Introduction
In the last decade, The Cancer Genome Atlas (TCGA) consortium has generated multi-platform cancer genomics data, including somatic mutations, copy number alterations, gene expression, and DNA methylation, in more than 20 cancer types (1) . TCGA also generated some proteomics data using the Reverse Phase Protein Array (RPPA) platform, measuring protein levels in tumors for about 150 proteins and 50 phosphoproteins (2) . However, the RPPA technology is limited by the availability and binding efficiency of available antibodies for protein and post-translational modification detection. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) consortium is aimed at characterizing the protein inventory in tumors by leveraging the latest developments in mass spectrometry-based discovery proteomics. The initial CPTAC projects have generated extensive mass spectrometry-based proteomics data on TCGA tumors of breast cancer (proteome and phosphoproteome) (3, 4) , ovarian cancer (proteome, phosphoproteome, and glycoproteome) (5, 6) , and colorectal cancer (proteome only, with matching normal samples) (7, 8, 9) . Currently, the consortium is extending the proteomics analysis to genomically characterized tumor samples for other cancer types.
By profiling the same cancer patients already profiled by TCGA, CPTAC results provide a unique opportunity for performing integrative analysis of cancer genomics and proteomics data, which can link proteomics to genotypes and potentially phenotypes in cancer. There is a growing demand for exploratory analysis tools that integrate cancer genomics, proteomics and clinical data and provide easy access to the multi-dimensional datasets, and efforts such as TCPA and LinkedOmics have started to fill this gap (10, 11) . The cBioPortal for Cancer Genomics has been one of the leading resources for analyzing cancer genomics data, including all TCGA projects and many data sets curated from the literature (12, 13) . cBioPortal features a biologist-friendly interface, biology-aware visualization, and integrative analysis features, making it one of the most popular resources in the community of cancer genomics researchers, especially biologists without bioinformatics skills.
We have updated cBioPortal to integrate the CPTAC mass spectrometry based proteomics data, making the high quality proteomics data easily accessible for visualization and analysis in the context of cancer genomics. First, we developed a data transformation pipeline for converting mass spectrometry results produced by CPTAC members into a data format that is compatible with the cBioPortal data pipeline. This data transformation pipeline is also applicable for uploading non-CPTAC mass spectrometry results into cBioPortal, as they become available.
In order to better support integrative analysis of genomics and proteomics data, we have made various adjustments to the cBioPortal interface, including protein expression heatmap visualization in OncoPrint (graphic summary of gene-level data and clinical attributes), correlation analysis, and differential analysis. By integrating CPTAC data into cBioPortal, we aim to increase the accessibility of mass spectrometry-based proteomics data to cancer researchers in the context of cancer genomics and provide researchers with an intuitive interface to explore and analyze interactions between genomics and proteomics in cancer.
Experimental Procedures and Results
Introduction to the cBioPortal for cancer genomics interface -The public instance of the cBioPortal hosts more than 100 studies, including all TCGA projects and published studies from the literature. A key step in cBioPortal that enables integration of various datasets is gene-level mapping of the data. For example, by mapping mutations, copy number, and gene expression onto a gene, the visualization and analysis features of the cBioPortal supports studying different types of gene alterations in tumors simultaneously, including, among others: Transforming CPTAC data for the cBioPortal database -Processed CPTAC mass spectrometry data was downloaded from the CPTAC Data Portal (https://cptac-data-portal.georgetown.edu/).
The downloaded data had been processed using the Common Data Analysis Pipeline (CDAP) (14) , which standardizes the treatment of data across the consortium. CDAP software is flexible to accommodate different types of mass spectrometry data. Peptides are identified using MS-GF+ (15) , and the protein FASTA file used is a concatenation of RefSeq H. sapiens build 37
with the sequence for S. scrofa trypsinogen added. The MS-GF+ phosphopeptide assignments are fed into PhosphoRS to obtain phosphosite localizations. The results are made into both peptide-level and protein-level tab-separated (TSV) files consisting of iTRAQ ratios for breast and ovarian sample and precursor area intensity measurements for the colon samples.
We mapped the proteomics data onto genes because the query interface and analysis features of cBioPortal are gene-centric, so protein levels were mapped directly to their corresponding genes by mapping RefSeq protein IDs to Hugo gene symbols. For PTM data, we focused on the phosphoproteomics data. For phosphoprotein levels (currently, the only PTM added to cBioPortal), we make special symbols for them with the following pattern:
<HUGO gene symbol>_P{S,T,Y}<AA modified>
For example, EIF4EBP1 phosphorylated at the serine located at position 65 is denoted as EIF4EBP1_PS65. In order to easily access phosphoproteins while querying, each phosphoprotein in the database has as an alias PHOSPHO<HUGO gene symbol> which, when queried, brings up a list of phosphoproteins sharing that alias. Users can choose the phosphoproteins that they want to see displayed. Future PTMs will be associated with similar aliases as they are added.
In order for the data to be used by cBioPortal, the distribution of intensities per sample must be reasonably close to a normal distribution, since the interface relies on Z-scores for much of its computations and displays. an unusual mutation spectrum that is enriched for the thiamine to guanine transversion. The patient seems to have a lower than average diagnosis age and overall survival, and the patient has been classified as having breast cancer lobular carcinoma. Interestingly, this tumor sample has three oncogenic ERBB2 mutations (shown when hovering over the sample), and its ERBB2
is expressed above average in mRNA but below average in protein and all available phosphosites.
Other tabs can also allow users to explore potential correlations in depth. For example, the Plots tab can be used to select the DNA copy number, methylation, gene expression, or protein levels from the list of queried genes and post-translational modifications, which allows the user to browse the Pearson and Spearman correlations between the protein levels of ERBB2 and its phosphosites. By modifying the query to select other cancer types, it is also possible to see how these correlations shift across cancers ( Figure S1 ).
To illustrate the value of data exploration using well-established examples, we centered on ERBB2, which is a known oncogene in breast and ovarian cancer. The gene sequences of ERBB2 and GRB7 lie on the same amplicon on chromosome 17q12-21 (17) . It has been shown that GRB7 can act as an ERBB2-dependent oncogene by enhancing ERBB2 phosphorylation (18). Using the cBioPortal Plots tab, users can see a perfect co-occurrence of copy number categorizations between ERBB2 and GRB7. This persists as a high correlation between copy number and mRNA levels and mRNA and protein levels. ERBB4, on the other hand, is in the same receptor family as ERBB2, and it is not located on the same amplicon so copy number changes are not correlated. Also mRNA levels of of ERBB2 and ERBB4 are not correlated but protein levels are correlated consistent with ERBB2 and ERBB4 forming a heteromeric complex ( Figure S2 ) (19).
Use case 2: Exploring cBioPortal data through its web API using the R package cgdsr to
access the full database now loaded with mass spectrometry data -While the cBioPortal web interface offers many pre-built analysis tools for exploratory analysis, users may want to perform further custom and automated analysis of the data that cannot be done on the interface. The cBioPortal public database has integrated all the different genomic profiles from TCGA, CPTAC, and other sources together into a MySQL database, and made the data available programmatically via a web application program interface (API). The R package cgdsr accesses the all the genomics and clinical data by connecting to the web API. An example R script to access cBioPortal data including the proteomics data is provided here (see Supplementary Information 6). In this example, we looked at how well PAM50-based subtypes are conserved when using mass spectrometry-based proteomics values for clustering. Using the " ward.D2 " setting for the histfun parameter of heatmap.2 in R, we performed hierarchical clustering on the 77 breast cancer samples containing mass spectrometry data and color-coded the samples by their PAM50 subtype classification (see Figure S3) . A more rigorous version of this analysis has been performed on the same data (4), but this example shows the streamlining of data retrieval and analysis that is achieved by wrapping the CPTAC data with the cBioPortal API (see Supplementary Script S1).
Use case 3: Loading unpublished or institution-specific proteomics data onto a local private
cBioPortal instance for integrative analysis -Over 30 institutions now have a private instance of cBioPortal hosting institution-specific research and/or clinical data, which allows researchers to perform cBioPortal-enabled exploratory analysis on private institutional data. An import pipeline now exists to convert mass spectrometry data processed by CDAP into a format for effective loading into the cBioPortal database. All features and functionalities available on the public interface is available for private institutional data which can be supplemented with the public data for richer exploratory analysis. Instructions for the deployment of a private instance can be found in the documentation (see Supplementary Information 7).
Discussions and Conclusion
Being able to easily integrate multiple omics domains in order to synthesize them into actionable insights is a modern challenge created by the proliferation of high-throughput sequencing and spectrometry techniques. To address this challenge, the cBioPortal has been developed to provide a public and user-friendly interface for performing interactive and integrative data exploration, analysis and visualization. To incorporate the mass spectrometry data from CPTAC,
we have updated the cBioPortal data pipeline and the public web interface. The data process pipeline not only enables integration of current and future CPTAC data, but also allows private mass spectrometry data to be loaded into databases of institutional instances of the cBioPortal.
We also updated the web interface and web API of cBioPortal to support easy access and better visualization and analysis of the mass spectrometry data in the context of cancer genomics and clinical datasets.
The inclusion of mass spectrometry data from CPTAC in the cBioPortal is a significant step towards better understanding of the whole molecular profile of various cancer types. In TCGA projects, RPPA was adopted as the proteomics platform to profile key proteins and has generated a valuable resource for study cancer proteomics and its association with cancer genomics. However, due to the availability of antibodies, the coverage of RPPA for measuring the proteome (both total proteins and PTMs) is limited, while mass spectrometry can profile a large portion of the proteome and many different types of PTMs without the initial data collection biased by the availability of detection agents (for example, see comparison in Figure S4 ). At the moment, the number of tumors analyzed mass spectrometry is still considerably smaller than those analyzed by RPPA (see Table 1 ), but with the continuous efforts such as CPTAC, we expect to see a large increase of the number of tumors in more cancer types profiled by mass spectrometry. All in all, integrating mass spectrometry data with genomics data provides a new opportunity to uncover novel associations between genome, proteome and phenotype in cancer.
the seven-transmembrane receptor with extracellular six-cystein domain. Intl. J. Onco. Script S1. The script file used for generating the heatmap shown in Figure S3 is as follows:
# open an instance and test mycgds <-CGDS ( "http://www.cbioportal.org/public-portal/") test ( mycgds)
# view and print all cancer studies studies <-getCancerStudies ( mycgds) # select breast cancer study from query menu name cancer_study <-"Breast Invasive Carcinoma (TCGA, Provisional)" study_id <-studies [ studies$name == cancer_study , "cancer_study_id"]
# view and print all patient cases cases <-getCaseLists ( mycgds , study_id)
# view and print all genetic profiles profiles <-getGeneticProfiles ( mycgds , study_id)
# select mass spec cases case_id <-cases [ cases$case_list_name == "Protein Quantification (Mass Spec)" , "case_list_id"] profile_id <-profiles [ profiles$genetic_profile_name == "Protein levels (mass spectrometry by CPTAC)" , "genetic_profile_id"] # get genetic profile data from PAM50 genes <-c ( "UBE2T" , "BIRC5" , "NUF2" , "CDC6" , "CCNB1" , "TYMS" , "MYBL2" , "CEP55" , "MELK" , "NDC80" , "RRM2" , "UBE2C" , "CENPF" , "PTTG1" , "EXO1" , "ORC6L" , "ANLN" , "CCNE1" , "CDC20" , "MKI67" , "KIF2C" , "ACTR3B" , "MYC" , "EGFR" , "KRT5" , "PHGDH" , "CDH3" , "MIA" , "KRT17" , "FOXC1" , "SFRP1" , "KRT14" , "ESR1" , "SLC39A6" , "BAG1" , "MAPT" , "PGR" , "CXXC5" , "MLPH" , "BCL2" , "MDM2" , "NAT1" , "FOXA1" , "BLVRA" , "MMP11" , "GPR160" , "FGFR4" , "GRB7" , "TMEM45B" , "ERBB2") ms_data <-getProfileData ( mycgds , genes , profile_id , case_id) # filter out uninformative genes ms_data[is.na(ms_data)] <-0 # transpose and convert to matrix ms_scaled <-as . matrix ( t ( ms_data )) # fetch TCGA subtypes # URL: https://tcga-data.nci.nih.gov/docs/publications/brca_2012/BRCA.547.PAM50.SigClust.Subtypes.txt subtypes <-read . along with the mass spectrometry data for all available phosphosites for ERBB2 containing any non-NaN data across all samples. Clinical information for this example includes the mutation spectrum, which is a segmented bar plot of the fraction that each transition or transversion occurs within the sample (though not necessarily for the gene set specified); diagnosis age; overall survival, which is the survival in months from the time of diagnosis; the detailed cancer type, which in this case indicates if the breast cancer was lobular or ductal; and the HER2 (ERBB2) IHC score, which indicates whether or not immunohistochemistry (IHC) staining was able to detect ERBB2 receptors on the surface of the tumors (negative corresponds to a score of 0-1, equivocal corresponds to a score of 2, and 3+ is positive for ERBB2). Query Menu Location refers to the location in the tree structure that organizes the cancer studies on the homepage of cBioPortal where the initial query parameters are set. Figure 1 . Oncoprint of ERBB2 alterations including heatmap of its protein levels and the levels of ERBB2 phosphosites. Samples consisted of the 77 TCGA breast cancer patient samples containing genomic alterations, RNAseq RSEM data, and mass spectrometry data for ERBB2 along with the mass spectrometry data for all available phosphosites for ERBB2 containing any non-NaN data across all samples. Clinical information for this example includes the mutation spectrum, which is a segmented bar plot of the fraction that each transition or transversion occurs within the sample (though not necessarily for the gene set specified); diagnosis age; overall survival, which is the survival in months from the time of diagnosis; the detailed cancer type, which in this case indicates if the breast cancer was lobular or ductal; and the HER2 (ERBB2) IHC score, which indicates whether or not immunohistochemistry (IHC) staining was able to detect ERBB2 receptors on the surface of the tumors (negative corresponds to a score of 0-1, equivocal corresponds to a score of 2, and 3+ is positive for ERBB2). 
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